The market for treating Subcutaneous Neurofibroma, a manifestation often associated with Neurofibromatosis Type 1 (NF1), represents a challenging and highly specialized segment within the rare disease therapeutic area. While many subcutaneous neurofibromas are benign, their multiplicity, potential for malignant transformation, and high patient burden (including chronic pain, cosmetic...